Three New Members to Lead the American Society of Hematology

“It is exciting to have such a diverse and accomplished group of leaders helping to guide the society as we work with policymakers, educators, researchers, clinicians, patients, and other stakeholders to shape the future of hematology and work toward our ultimate goal of conquering blood diseases worldwide,” Kenneth C. Anderson, MD, of the Lebow Institute for Myeloma Therapeutics and the Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute, and the 2017 president of ASH, said in a statement.

Stephanie Lee, a member of the Fred Hutchinson Cancer Research Center and professor at the University of Washington in Seattle, Washington, is focused on outcomes and health services research for hematologic malignancies and allogeneic hematopoietic stem cell transplantation, including special attention on chronic graft-versus-host disease.

She will serve a 1-year term as vice president followed by successive terms as president-elect and then as president. As a long-term member of ASH, Stephanie Lee has served in multiple leadership roles, including as former chair of the Scholar Awards Program Study Section and secretary of ASH. In her new role as vice president, she is seeking to strengthen public appreciation and understanding of hematology research in addition to encouraging other members to become more involved in ASH’s programs.

Agnes Lee is a professor of medicine at the University of British Columbia (UBC), director of the Thrombosis Program at Vancouver Coastal Health and UBC, and director of the Hematology Research Program at Vancouver General Hospital. She is well known for her research into cancer-associated thrombosis, catheter-related thrombosis, and anticoagulants.

She will serve a 4-year term as a councilor on ASH’s Executive Committee. Agnes Lee has served as education program co-chair for the 2012 ASH Annual Meeting; program co-chair for the Highlights of ASH meetings in North America, Asia, and Latin America; and as a member of the editorial board for the journalBloodduring her 19 years at ASH. In addition to her new role, she will also continue on as a member of the Awards Committee, Small Meetings Oversight Subcommittee, and Guideline Panel on Venous Thromboembolism in Patients with Cancer.

Mikhael will also serve a 4-year term as councilor, in addition to his roles as professor of medicine at Mayo Clinic in Arizona, deputy director of the Mayo Clinic Cancer Center, and associate dean at Mayo Clinic School of Graduate Medicine Education. Mikhael researches multiple myeloma/plasma cells disorders, pharmaco-economics, and education and communication skills in medicine.

During his 17 years with ASH, he has served as education program co-chair for the ASH Annual Meeting; program co-chair for Highlights of ASH in North America, Asia, and Latin America; and co-director of the ASH Clinical Research Training Institute (CRTI). At present, Mikhael serves on the steering committee of the CRTI program and as chair of the ASH Committee on Communications.